Stereotactic biopsy for intracranial lesions: clinical-pathological compatibility in 60 patients
- PMID: 20069220
- DOI: 10.1590/s0004-282x2009000600019
Stereotactic biopsy for intracranial lesions: clinical-pathological compatibility in 60 patients
Abstract
Objective: Image guided stereotactic biopsy (SB) provides cerebral tissue samples for histological analysis from minimal lesions or those that are located in deep regions, being crucial in the elaboration of therapeutic strategies, as well as the prevention of unnecessary neurosurgical interventions.
Method: Sixty patients with central nervous lesions underwent SB from November 1999 to March 2008. They were followed up to 65 months. Preoperative diagnosis was based on clinical presentation and neuro-radiological features, pathologic diagnosis, clinical outcome. The compatibility of these findings with the pathologic diagnosis was analyzed.
Results: Considering diagnosis confirmation when inflammatory hypothesis were made, our accuracy was of 76%, with 94% of those cases having clinic-pathological correspondence after an average of 65.2 months of follow up. Considering diagnosis confirmation with the preoperative hypothesis of neoplasm, our accuracy was of 69% with 90% of these cases having clinic-pathological correspondence after an average of 47.3 months of follow-up. Morbidity rate was of 5% and mortality was zero. The diagnosis rate was 95%.
Conclusion: Stereotactic biopsy represents a safe and precise method for diagnosis. Anatomic and histopathological analyses have high compatibility with long-term clinical outcome.
Similar articles
-
Computerized Tomography-Guided Stereotactic Biopsy of Intracranial Lesions: Report of 500 Consecutive Cases.Turk Neurosurg. 2017;27(3):395-400. doi: 10.5137/1019-5149.JTN.16280-15.1. Turk Neurosurg. 2017. PMID: 27593799
-
The safety and diagnostic value of frame-based and CT-guided stereotactic brain biopsy technique.Turk Neurosurg. 2011;21(4):582-90. Turk Neurosurg. 2011. PMID: 22194120
-
Stereotactic biopsy for intracranial lesions: reliability and its impact on the planning of treatment.Acta Neurochir (Wien). 2003 Jul;145(7):547-54; discussion 554-5. doi: 10.1007/s00701-003-0048-8. Acta Neurochir (Wien). 2003. PMID: 12910397
-
[Stereotactic biopsy for intracranial deep lesions].Zhonghua Yi Xue Za Zhi. 2002 Feb 25;82(4):225-8. Zhonghua Yi Xue Za Zhi. 2002. PMID: 11953166 Chinese.
-
Acute demyelination: diagnostic difficulties and the need for brain biopsy.Acta Neurochir (Wien). 2003 Nov;145(11):961-9; discussion 969. doi: 10.1007/s00701-003-0113-3. Acta Neurochir (Wien). 2003. PMID: 14628201 Review.
Cited by
-
Retrospective Evaluation of Cases Undergoing Stereotaxic Brain Biopsy.Asian J Neurosurg. 2023 Sep 27;18(3):602-608. doi: 10.1055/s-0043-1774821. eCollection 2023 Sep. Asian J Neurosurg. 2023. PMID: 38152506 Free PMC article.
-
Intraoperative MRI for Brain Tumors.J Neurooncol. 2021 Feb;151(3):479-490. doi: 10.1007/s11060-020-03667-6. Epub 2021 Feb 21. J Neurooncol. 2021. PMID: 33611714 Review.
-
Diagnostic yield of stereotactic needle-biopsies of sub-cubic centimeter intracranial lesions.Surg Neurol Int. 2013 Apr 17;4(Suppl 3):S176-81. doi: 10.4103/2152-7806.110677. Print 2013. Surg Neurol Int. 2013. PMID: 23682345 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical